Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer

Maturitas ◽  
2010 ◽  
Vol 66 (3) ◽  
pp. 291-297 ◽  
Author(s):  
Xavier Nogues ◽  
Sonia Servitja ◽  
Maria Jesus Peña ◽  
Daniel Prieto-Alhambra ◽  
Rosa Nadal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Bone Mineral ◽  
Aromatase Inhibitors ◽  
Mineral Density

scholarly journals Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors

2017 ◽  
Vol 13 (5) ◽  
pp. e505-e515 ◽  
Author(s):  
Jamie Stratton ◽  
Xin Hu ◽  
Pamela R. Soulos ◽  
Amy J. Davidoff ◽  
Lajos Pusztai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Aromatase Inhibitors ◽  
Early Stage ◽  
Mineral Density ◽  
Dxa Scan ◽  
Bone Mineral Density Testing

Purpose: In postmenopausal women with breast cancer treated with aromatase inhibitors (AIs), most expert panels advise baseline bone mineral density testing with a dual-energy x-ray absorptiometry (DXA) scan repeated every 1 to 2 years. How often this recommendation is followed is unclear. Methods: We performed a retrospective analysis of women with stage I to III breast cancer who started AI therapy from January 1, 2008, to December 31, 2010, with follow-up through December 31, 2012, by using the SEER-Medicare database. Selection criteria included AI use for ≥ 6 months and no recent osteoporosis diagnosis or bisphosphonate use. We used multivariable logistic regression to investigate associations between patient characteristics and receipt of a baseline DXA scan. In patients who continued AI treatment, we assessed rates of follow-up scans. Results: In the sample of 2,409 patients (median age, 74 years), 51.0% received a baseline DXA scan. Demographic characteristics associated with the absence of a baseline DXA scan were older age (85 to 94 years v 67 to 69 years; odds ratio [OR], 0.62; 95% CI, 0.42 to 0.92) and black v white race (OR, 0.68; 95% CI, 0.47 to 0.97). Among patients who underwent a baseline DXA scan and continued AI for 3 years, 28.0% had a repeat DXA scan within 2 years and 65.9% within 3 years. In aggregate, of the 1,164 patients who continued with AI treatment for 3 years, only 34.5% had both a baseline and at least one DXA scan during the 3-year follow-up period. Conclusion: The majority of older Medicare beneficiaries with breast cancer treated with AIs do not undergo appropriate bone mineral density evaluation.

Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women

Maturitas ◽  
1991 ◽  
Vol 13 (1) ◽  
pp. 87-88
Author(s):  
T. Fornander ◽  
L.E. Rutqvist ◽  
H.E. Sjoberg ◽  
L. Blomqvist ◽  
A. Mattsson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Bone Mineral ◽  
Adjuvant Tamoxifen ◽  
Mineral Density

scholarly journals Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer

Medicine ◽  
2019 ◽  
Vol 98 (32) ◽  
pp. e16770 ◽  
Author(s):  
Koichi Sakaguchi ◽  
Hisako Ono ◽  
Katsuhiko Nakatsukasa ◽  
Takashi Ishikawa ◽  
Yoshie Hasegawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Early Breast Cancer ◽  
Bone Mineral ◽  
Aromatase Inhibitors ◽  
Mineral Density ◽  
Normal Bone ◽  
Normal Bone Mineral Density

Changes in bone mineral density during 5 years of adjuvant exemestane therapy in postmenopausal women with early breast cancer.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e12003-e12003
Author(s):  
Akira Hirano ◽  
Hiroaki Inoue ◽  
Kaoru Ogura ◽  
Akinori Hattori ◽  
Hiroko Yukawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Bone Mineral ◽  
Mineral Density
Sign in / Sign up

Export Citation Format

Share Document